Search
Geron Corp
GERNAdd to Watchlist
1.360USD
+0.090+7.09%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
870.20MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Geron Corp is 7.67, ranking 275 out of 387 in the Biotechnology & Medical Research industry. The average price target is 4.00, with a high of 5.00 and a low of 1.00.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
3.400
Target Price
+161.54%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Geron Corp
GERN
6
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Geron Corp's expected revenue for the next quarter?
Geron Corp's expected revenue is 55.21M.
What is Geron Corp's price target?
Analysts forecast that Geron Corp's price target is USD 4.00, with the highest forecast at USD 5.00 and the lowest forecast at USD 1.00.
How have Geron CorpGERN's recent earnings per share performed?
The market expectation was USD -0.01, while Geron CorpGERN's earnings per share (EPS) for the previous quarter was USD -0.04. EPS for the next quarter is expected at USD -0.01.
What is the analyst rating for Geron Corp?
Based on the ratings of Geron Corp's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.